Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus Sonrotoclax vs Zanubrutinib in Untreated Older Patients with CLL/SLL
NCT07321652Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2026
- Primary completion
- Sep 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of sonrotoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Cancer and Leukemia Group B. Started Apr 2026; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07321652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321652.